|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A brief clinical tool to assess physical function:the mini-physical performance test显示文摘 | Wilkins CH Roe CM Moms JC | 2010 | Arch Gerontol Geriatr2010，50，1： | 1 |
| 2 | The clinical trail of TRAIL显示文摘 | Duiker EW Mom CH de Jong S | 2006 | Cancer2006，42，14： | 1 |
| 3 | The clinical trail of TRAIL显示文摘 | Duiker EW Mom CH de Jong S | 2006 | Eur J Cancer2006，42，14： | 1 |
| 4 | Granulosa cell tumors of the ovary:the clinical value of serum inhibin A and B levels in a large single center cohort显示文摘 | Mom CH Engelen MJ Willemse PH | 2007 | Gynecol Oncol2007，，： | 1 |
| 5 | Hot flushes in breast cancer patients显示文摘 | Mom CH Buijs C Wiuemse PH | 2006 | Crit Rev Oncol Hematol2006，57，1： | 1 |
| 6 | A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours显示文摘 | ESKENS FA MOM CH PLANTING AS | 2008 | Br J Cancer2008，98，1： | 1 |
| 7 | A phase I doseescalation study of BIBW 2992 , an irreversible dual inhibitor ofepidermal growth factor receptor 1 ( EGFR) and 2 ( HER2) tyro-sine kinase in a 2-week on,2-week off schedule in patients withadvanced solid tumours显示文摘 | ESKENS FA MOM CH PLANTING AS ^ al | 2008 | Br J Cancer2008，98，1： | 1 |
| 8 | A phase I dose escalation study of BIBW 2992,an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on,2-week off schedule in patients with advanced solid tumours显示文摘 | Eskens FA Mom CH Planting AS | | 0，，1： | 1 |
| 9 | A phase I dose es- calation study of BIBW 2992, an irreversible dual inhibitor of ep- idermal growth factor receptor 1 (EGFR) and 2 ( HER2 ) tyro- sine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours 显示文摘 | Eskens FA Mom CH Plantingetal AS | 2008 | Br J Cancer2008，98，1： | 1 |
| 10 | A phase I dose escalation study of BIBW 2992,an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on,2-week off schedule in patients with advanced solid tumours显示文摘 | Eskens FA Mom CH Planting AS | 2008 | Br J Cancer2008，98，： | 1 |
| 11 | Granulosa cell tumors of the ovary:the clinical value of serum inhibin A and B levels in a large single center cohort显示文摘 | Mom CH Engelen MJ Willemse PH | 2007 | Gynecol Oncol2007，105，： | 1 |
| 12 | Mapatumumab,a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase 1 b study in patients with advanced solid malignancies显示文摘 | Mom CH Sleijfer S Gietema JA | 2005 | Clin Cancer Res2005，11，： | 1 |
| 13 | Hot flushes in breast cancer patients 显示文摘 | Mom CH Buijs C Wiuemse PH | 2006 | Crit Rev Oncol Hematol2006，57，1： | 1 |
| 14 | The clinical trail of TRAIL 显示文摘 | Duiker EW Mom CH Jong Sde | 2006 | European journal cancer2006，42，14： | 1 |
| 15 | A phase Ⅰ dose escalation study of BIBW 2992,an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on,2-week off schedule in patients with advanced solid tumours显示文摘 | Eskens FA Mom CH Planting AS | 2008 | Br J Cancer2008，98，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员